Shares of ImmuPharma plc (LON:IMM – Get Free Report) rose 16.2% on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.05 ($0.04). Approximately 5,196,025 shares were traded during trading, a decline of 77% from the average daily volume of 22,992,301 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Stock Performance
The firm has a market cap of £14.58 million, a P/E ratio of -350.00 and a beta of 1.53. The business has a 50-day simple moving average of GBX 1.56 and a 200 day simple moving average of GBX 1.68.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Investing in Travel Stocks Benefits
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What is a Low P/E Ratio and What Does it Tell Investors?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
